Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StroMel in moderate to severe knee osteoarthritis
NCT04750252Phase 2Not yet recruiting
- Sponsor
- Akan Biosciences
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of StroMel in knee osteoarthritis (OA), sponsored by Akan Biosciences. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
StroMel
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT04750252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04750252.